Background Trypanosoma cruzi, an intracellular protozoan parasite that infects humans and other mammalian hosts, is the etiologic agent in Chagas disease. This parasite can invade a wide variety of mammalian cells. The mechanism(s) by which T. cruzi invades its host cell is not completely understood. The activation of many signaling receptors during invasion has been reported; however, the exact mechanism by which parasites cross the host cell membrane barrier and trigger fusion of the parasitophorous vacuole with lysosomes is not understood. Methodology/Principal Findings In order to explore the role of the Low Density Lipoprotein receptor (LDLr) in T. cruzi invasion, we evaluated LDLr parasite interactions using immunoblot and immunofluorescence (IFA) techniques. These experiments demonstrated that T. cruzi infection increases LDLr levels in infected host cells, inhibition or disruption of LDLr reduces parasite load in infected cells, T. cruzi directly binds recombinant LDLr, and LDLr-dependent T. cruzi invasion requires PIP2/3. qPCR analysis demonstrated a massive increase in LDLr mRNA (8000 fold) in the heart of T. cruzi infected mice, which is observed as early as 15 days after infection. IFA shows a co-localization of both LDL and LDLr with parasites in infected heart. Conclusions/Significance These data highlight, for the first time, that LDLr is involved in host cell invasion by this parasite and the subsequent fusion of the parasitophorous vacuole with the host cell lysosomal compartment. The model suggested by this study unifies previous models of host cell invasion for this pathogenic protozoon. Overall, these data indicate that T. cruzi targets LDLr and its family members during invasion. Binding to LDL likely facilitates parasite entry into host cells. The observations in this report suggest that therapeutic strategies based on the interaction of T. cruzi and the LDLr pathway should be pursued as possible targets to modify the pathogenesis of disease following infection.
References
[1]
Brown MS, Goldstein JL (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34–47. doi: 10.1126/science.3513311
[2]
Sudhof TC, Russel DW, Goldstein JL, Brown MS (1985) Casette of eight exons shared by genes for LDL receptor and EGF pecursor. Science 228: 893–95. doi: 10.1126/science.3873704
[3]
Südhof TC, Goldstein JL, Brown MS, Russell DW (1985) The LDL receptor gene: a mosaic of exons shared with different proteins. Science 228: 815–22. doi: 10.1126/science.2988123
[4]
Yamamoto T, Bishop RW, Brown MS, Goldstein JL, Russell DW (1986) Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit. Science 232: 1230–1237. doi: 10.1126/science.3010466
[5]
Chen WJ, Goldstein L, Brown MS (1990) NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor. J Biol Chem 265: 3116–3123.
[6]
Strickland DK, Gonias SL, Arfraves WS (2002) Diverse roles for the LDL receptor family. Trends in Endocrinology & Metabolism 13: 66–73. doi: 10.1016/S1043-2760(01)00526-4
[7]
Kumar A, Middleton A, Chambers TC, Mehta KD (1998) Differential roles of extracellular signal-regulated kinase-1/2 andp38 MAPK in interleukin-1b and tumor necrosis factor A-inducedlow density lipoprotein receptor expression in HepG2 cells. J Biol Chem 273: 15742–15748. doi: 10.1074/jbc.273.25.15742
Streicher RJ, Kotzka D, Muller-Wieland G, Siemeister M, Munck HA, et al. (1996) SREBP-1 mediates activationof the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-1. J Biol Chem 271: 7128–7133. doi: 10.1074/jbc.271.12.7128
[10]
Auwerx JH, Chait A, Wolfbauer G, Deeb SS (1999) Involvement of second messengers in regulation of the low-density lipoprotein receptor gene. Mol Cell Biol 9: 18194–18199.
[11]
FitzGerald DJ, Fryling CM, Zdanovsky A, Saelinger CB, Kounnas M, et al. (1995) Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein. J Cell Biol1 29: 1533–1541. doi: 10.1083/jcb.129.6.1533
[12]
Simone G, Carolina OR, Juliana FVS, Fabio VB, Maurício MR, et al. (2005) Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrobial Agents and Chemotherapy 49: 1521–1528. doi: 10.1128/AAC.49.4.1521-1528.2005
[13]
Gopikrishna P, Ramesh MG, Ijaz AK, Victor SN, Balendu CV (2007) Clinical aspects of the Chagas' heart disease. International Journal of Cardiology 115: 279–283. doi: 10.1016/j.ijcard.2006.03.004
[14]
Tanowitz HB, Weiss LM (2009) Parasitic diseases, diagnostic approaches, and therapies. Interdiscip Perspect Infect Dis. 2009. 893890 p.
Nagajyothi F, Desruisseaux MS, Thiruvur N, Weiss LM, Braunstein VL, et al. (2008) Trypanosoma cruzi infection of cultured adipocytes results in an inflammatory phenotype. Obesity 16: 1992–1997. doi: 10.1038/oby.2008.331
[17]
Ley V, Robbins ES, Nussenzweig V, Andrews NW (1990) The exit of Trypanosoma cruzi from the phagosome is inhibited by raising the pH of acidic compartments J Exp Med 171: 401–413. doi: 10.1084/jem.171.2.401
[18]
Tardieux I, Webster P, Ravesloot J, Boron W, Lunn JA, et al. (1992) Lysosome recruitment and fusion are early events required for trypanosome invasion of mammalian cells. Cell 71: 1117–1130. doi: 10.1016/S0092-8674(05)80061-3
[19]
Bakker AC, Webster P, Jacob WA, Andrews NW (1997) Homotypic fusion between aggregated lysosomes triggered by elevated [Ca2+] in fibroblasts. J Cell Sci 110: 2227–2238.
[20]
Rodríguez AE, Samoff M, Rioult A, Chung , Andrews NW (1996) Host cell invasion by trypanosomes requires lysosomes and microtubule/kinesin-mediated transport. J Cell Biol 134: 349–362. doi: 10.1083/jcb.134.2.349
[21]
Wilkowsky SE, Barbieri MA, Stahl P, Isola ELD (2001) Trypanosoma cruzi: Phosphatidylinositol 3-Kinase and Protein Kinase B activation is associated with parasite invasion. Exp Cell Res 264: 211–218. doi: 10.1006/excr.2000.5123
[22]
Maganto-Garcia E, Punzon C, Terhorst C, Fresno M (2008) Rab5 activation by Toll-like receptor 2 is required for Trypanosoma cruzi internalization and replication in Macrophages. Traffic 9: 1299–1315. doi: 10.1111/j.1600-0854.2008.00760.x
[23]
Todorov AG, Andrade D, Pesquero JB, Araujo RC, Bader M, et al. (2003) Trypanosoma cruzi induces edematogenic responses in mice and invades cardiomyocytes and endothelial cells in vitro by activating distinct kinin receptor (B1/B2) subtypes. FASEB J 17: 73–75. doi: 10.1096/fj.02-0477fje
[24]
Melo-Jorge M, Pereira PM (2007) The Chagas' disease parasite Trypanosoma cruzi exploits nerve growth factor receptor TrkA to infect mammalian hosts. Cell Host Microbe 14: 251–61. doi: 10.1016/j.chom.2007.05.006
[25]
Ming M, Ewen ME, Pereira ME (1995) Trypanosome invasion of mammalian cells requires activation of the TGF beta signaling pathway. Cell 82: 287–296. doi: 10.1016/0092-8674(95)90316-X
[26]
Rowin KS, Tanowitz HB, Wittner M, Nguyen HT, Nadal-Ginard B (1983) Inhibition of muscle differentiation by Trypanosoma cruzi. Proc Natl Acad Sci U S A 80: 6390–6394. doi: 10.1073/pnas.80.20.6390
[27]
Weiss LM, Laplace D, Takvorian PM, Tanowitz HB, Cali A, Wittner M (1995) A cell culture system for study of the development of Toxoplasma gondii bradyzoites. J Eukaryot Microbiol 42: 150–157. doi: 10.1111/j.1550-7408.1995.tb01556.x
[28]
Nam YJ, Mani K, Wu L, Peng CF, Calvert JW, et al. (2007) The apoptosis inhibitor ARC undergoes Ubiquitin-Proteasomal-mediated degradation in response to death stimuli identification of a degradation-resistant mutant. J Biol Chem 282: 5522–5528. doi: 10.1074/jbc.M609186200
[29]
Combs TP, Nagajyothi F, Mukherjee S, de Almeida CJ, Jelicks LA, et al. (2005) The adipocyte as an important target cell for Trypanosoma cruzi infection. J Biol Chem 280: 24085–24094. doi: 10.1074/jbc.M412802200
[30]
Robertson D, Savage K, Reis-Filho JS, Isacke CM (2008) Multiple immuno-fluorescencelabelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol 9: 13–23. doi: 10.1186/1471-2121-9-13
[31]
Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, et al. (1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92: 883–93. doi: 10.1172/JCI116663
[32]
Kara NM, Edward AF, Jan LB (2005) Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. PNAS 102: 2069–2074. doi: 10.1073/pnas.0409736102
[33]
Prioli RP, Rosenberg I, Pereira ME (1990) High- and low-density lipoproteins enhance infection of Trypanosoma cruzi in vitro. Mol Biochem Parasitol 15: 191–198. doi: 10.1016/0166-6851(90)90022-E
[34]
Woolsey AM, Sunwoo L, Petersen CA, Brachmann SM, Cantley LC, et al. (2003) Novel PI 3-kinase-dependent mechanisms of trypanosome invasion and vacuole maturation. J Cell Sci 116: 3611–3622. doi: 10.1242/jcs.00666
[35]
Barrias EM, Reignault LC, de Souza W, Tecia M, Carvalho (2010) Dynasore, a dynamin inhibitor, inhibits Trypanosoma cruzi entry into peritoneal macrophages. PLoS One 5: 1–11. doi: 10.1371/journal.pone.0007764
Villalta F, Scharfstein J, Ashton AW, Tyler KM, Guan F, et al. (2009) Perspectives on the Trypanosoma cruzi-host cell receptor interactions. Parasitol Res 104: 1251–1260. doi: 10.1007/s00436-009-1383-3
[38]
de Souza W, de Carvalho TM, Barrias ES (2010) Review on Trypanosoma cruzi: Host Cell Interaction. Int J Cell Biol. 2010 p.
[39]
Todorov AG, Einicker-Lamas M, de Castro SL, Oliveira MM, Guilherme A (2000) Activation of Host Cell Phosphatidylinositol 3-Kinases by Trypanosoma cruzi Infection. J Biol Chem 275: 32182–32186. doi: 10.1074/jbc.M909440199
[40]
Mehrabi MR, Sinzinger H, Ekmekcioglu C, Tamaddon F, Plesch K, et al. (2000) Accumulation of oxidized LDL in human semilunar valves correlates with coronary atherosclerosis Cardiovasc Res 45: 874–882. doi: 10.1016/S0008-6363(99)00389-2
[41]
Huang Y, Ghosh MJ, Lopes-Virella MF (1997) Transcriptional and post-transcriptional regulation of LDL receptor gene expression in PMA-treated THP-1 cells by LDL-containing immune complexes. J Lipid Res 38: 110–120.
